Last updated: February 23, 2026
EVEKEO (vericiguat) is a prescribed drug designed to treat chronic heart failure with reduced ejection fraction (HFrEF). Approved by the FDA in January 2023, it aims to reduce hospitalization and cardiovascular mortality in this patient subset. Its market performance hinges on regulatory approvals, clinical trial results, competitive landscape, and payer acceptance.
Regulatory Status and Launch Timing
- FDA Approval: January 2023.
- Indication: Heart failure with reduced ejection fraction (HFrEF).
- Market Launch: US initial, with potential expansions into Europe and Asia post-approval.
Market Size and Segmentation
- Global Heart Failure (HF) Market (2022): Estimated at $5.2 billion.
- HFrEF Submarket: Accounts for approximately 60%, translating to $3.12 billion.
- Patient Population (US): 6 million diagnosed; about 50% have HFrEF.
- Treatment Rate: Roughly 70% of eligible patients receive guideline-directed medical therapy (GDMT).
Competitive Landscape
- Key Competitors: Entresto (sacubitril/valsartan), beta-blockers, mineralocorticoid receptor antagonists.
- Differentiators: EVEKEO targets a specific pathway—soluble guanylate cyclase stimulation—offering an alternative for patients intolerant to standard therapies.
Pricing and Reimbursement
- Pricing in US: Estimated at $9,000–$12,000 annually.
- Payer Coverage: Limited early access; negotiations underway with major insurers.
- Expected Reimbursement Rate: Near 80% for approved indications, contingent on formulary inclusion.
Adoption Drivers
- Clinical Efficacy: Demonstrated in the VICTORIA trial showing reduction in CV death and HF hospitalization.
- Guideline Inclusion: Pending updates to HF treatment protocols to incorporate EVEKEO.
- Physician Awareness: Increases as more clinical data becomes available and educational efforts expand.
Market Penetration and Sales Forecasts
| Year |
Estimated US Sales (USD Millions) |
Market Penetration (%) |
Remarks |
| 2023 |
50–100 |
1–2% |
Limited launch, early adopters |
| 2024 |
200–400 |
3–6% |
Growing clinician familiarity |
| 2025 |
500–800 |
8–12% |
Broader adoption, comp expansion |
Worldwide sales are expected to follow the US trajectory with a lag of 1–2 years, driven by approvals and market access strategies in Europe and Asia.
Revenue Influences and Risks
- Pricing Pressure: Negotiations may limit future pricing.
- Market Penetration: Slow adoption due to entrenched standard-of-care treatments.
- Clinical Outcomes: Real-world data could reinforce or undermine efficacy perceptions.
- Regulatory Changes: New guidelines could streamline or complicate expansion.
Financial Outlook Summary
EVEKEO’s initial revenue stream remains modest due to late-stage entry into a competitive market. Long-term growth depends heavily on expanding indications, establishing clinical value, and improving payer and physician acceptance. Analysts project revenues could reach $1 billion globally within 5 years if adoption accelerates and pricing strategies remain favorable.
Key Takeaways
- EVEKEO became commercially available in early 2023.
- It targets a large, underserved segment within the heart failure market.
- The drug faces competition from established therapies but offers a novel pathway.
- Revenue growth depends on clinical acceptance, formulary inclusion, and geographic expansion.
- Long-term forecasts suggest potential billion-dollar revenues contingent on market penetration.
FAQs
1. What is the primary indication for EVEKEO?
Treatment of chronic heart failure with reduced ejection fraction (HFrEF).
2. How does EVEKEO compare to existing therapies?
It offers a different mechanism (soluble guanylate cyclase stimulation), suitable for patients intolerant to standard treatments.
3. What factors might hinder EVEKEO’s market penetration?
Entrenched existing therapies, pricing negotiations, and slow updates in clinical guidelines.
4. What is the expected timeline for global adoption?
US adoption is expected to peak within 2–3 years; international markets may follow within 4–6 years.
5. What are the main drivers for future revenue growth?
Clinical validation, inclusion in treatment guidelines, expanding indications, and broad payer acceptance.
References
[1] U.S. Food and Drug Administration. (2023). EVEKEO (vericiguat) approved for reducing cardiovascular mortality and heart failure hospitalization.
[2] Market Research Future. (2022). Global heart failure therapeutics market report.
[3] IQVIA. (2022). US heart failure prescription data.
